We are testing a new rifamycin solution for patients with mild to moderate left-sided ulcerative colitis. The study aims to see if it helps improve symptoms and induce remission compared to a placebo.
We are studying whether adding a specific clot-dissolving treatment helps improve recovery in patients with acute strokes who have already had successful blood flow restoration. This trial will also evaluate safety and costs associated with this treatment.
We are examining how contrast-enhanced ultrasound can help assess blood flow in the placenta for patients undergoing medical termination of pregnancy. This study compares cases of fetal growth restriction with those without to better understand placental health.
We are studying a combination of treatments for patients with anti-Hu-associated nerve damage due to cancer. The goal is to see if this early immunotherapy improves symptoms and helps patients live longer without cancer progression.
We are studying the safety of a new treatment for patients with myeloid malignancies. This research aims to understand how well the treatment is tolerated by patients.
We are studying how to find biomarkers that indicate a risk of bone disease in people taking glucocorticoids. This research may help improve monitoring and prevention strategies for affected individuals.
We are testing a new tracer for PET scans to see if it helps diagnose coronary artery disease in patients who may have it. The study will also assess the safety of this new diagnostic method.
We are investigating a new drug, IPH6501, for patients with relapsed or refractory Non-Hodgkin Lymphoma. The study focuses on its safety and early signs of effectiveness in treating this type of cancer.
We are comparing a high-dose flu vaccine to a standard-dose vaccine to see which one better reduces hospital visits for flu and pneumonia in older adults. This study aims to improve vaccine effectiveness for this age group.
We are studying a new combination therapy with pembrolizumab for men with metastatic castration-resistant prostate cancer. The trial aims to evaluate its safety and how well it reduces PSA levels compared to standard treatments.
We are investigating whether Sodium Oxybate can help reduce alcohol consumption in people with high drinking risk levels. This study aims to support individuals in maintaining abstinence from alcohol.
We are evaluating a new treatment for patients with multiple myeloma to see how safe it is and how well it works. This study will help us understand the maximum dose that can be tolerated.
We are studying the safety of bomedemstat for individuals with essential thrombocythemia, polycythemia vera, or myelofibrosis who participated in a previous study. The trial also examines how well the treatment manages these conditions over time.
We are studying whether a combination of lomustine and temozolomide improves survival for newly diagnosed glioblastoma patients with a specific genetic marker. This trial also looks at side effects and quality of life compared to standard treatment.
We are studying a new gene therapy to see if it is safe and effective for patients with severe Crigler-Najjar syndrome who need phototherapy. This trial will help us understand how it may improve their health and quality of life.
We are studying how different chemotherapy regimens combined with Keytruda affect the immune response in patients with early-stage triple-negative breast cancer. The goal is to find the most effective treatment approach for this specific cancer type.
We are evaluating whether a new stent and a shorter antiplatelet therapy can reduce complications in patients with coronary artery disease. This study compares these approaches to standard treatment options.
We are assessing a new treatment, ANX1502, for individuals with Primary Cold Agglutinin Disease. This study aims to understand its safety and how it affects the condition.
We are comparing two doses of a fertility medication to see which produces more healthy embryos in older women undergoing fertility treatment. This study aims to improve outcomes for women trying to conceive.
We are studying whether early treatment with candesartan can help prevent heart function decline in people with a genetic risk for dilated cardiomyopathy who currently have no symptoms. The trial also looks at the safety of this medication.